
Adobe (ADBE) Strikes New Deal with U.S. Government
Protect Your Portfolio Against Market Uncertainty
Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
GSA Acting Administrator Stephen Ehikian said that the agreement helps all federal agencies access top technology at the best possible prices. He added that under President Trump's administration, the GSA is focused on buying software more strategically across agencies instead of each agency buying separately. This change is meant to speed up government modernization and cut down on inefficiencies.
Unsurprisingly, Adobe's Chief Revenue Officer, Stephen Frieder, said that the company is proud to expand its work with the federal government. He said that the new deal will help agencies become more efficient, secure, and modern. Interestingly, the software bundle includes tools like Adobe Acrobat, Adobe Sign, Adobe Express, and Experience Manager Forms, which are all designed to help agencies go digital and reduce paperwork.
Is ADBE Stock a Good Buy?
Turning to Wall Street, analysts have a Moderate Buy consensus rating on ADBE stock based on 21 Buys, nine Holds, and zero Sells assigned in the past three months, as indicated by the graphic below. Furthermore, the average ADBE price target of $508.22 per share implies 32.2% upside potential.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
![[PREMIERING 5PM ET] These Are the Signs Xi Is Losing Power in China](/_next/image?url=https%3A%2F%2Fimg.theepochtimes.com%2Fassets%2Fuploads%2F2025%2F08%2F16%2Fid5902107-250815-ATL_Gordon-Chang_HD_TN_UPDATED.jpg&w=3840&q=100)
Epoch Times
43 minutes ago
- Epoch Times
[PREMIERING 5PM ET] These Are the Signs Xi Is Losing Power in China
As the Trump administration gives China another 90-day extension on elevated tariffs, I'm sitting down with China analyst Gordon Chang to get his read on U.S.–China trade talks, signs of infighting in Beijing and trouble for Xi Jinping, and the recent destruction of a Chinese coast guard vessel by a Chinese navy warship. Chang ...
Yahoo
an hour ago
- Yahoo
Ryvyl Second Quarter 2025 Earnings: US$0.36 loss per share (vs US$1.88 loss in 2Q 2024)
Ryvyl (NASDAQ:RVYL) Second Quarter 2025 Results Key Financial Results Revenue: US$2.78m (down 77% from 2Q 2024). Net loss: US$3.84m (loss narrowed by 68% from 2Q 2024). US$0.36 loss per share (improved from US$1.88 loss in 2Q 2024). Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. All figures shown in the chart above are for the trailing 12 month (TTM) period Ryvyl shares are down 5.8% from a week ago. Risk Analysis Before we wrap up, we've discovered 5 warning signs for Ryvyl (4 can't be ignored!) that you should be aware of. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Tonix Pharmaceuticals Holding Second Quarter 2025 Earnings: Misses Expectations
Tonix Pharmaceuticals Holding (NASDAQ:TNXP) Second Quarter 2025 Results Key Financial Results Net loss: US$28.3m (loss narrowed by 64% from 2Q 2024). US$3.86 loss per share (improved from US$1,921 loss in 2Q 2024). Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. All figures shown in the chart above are for the trailing 12 month (TTM) period Tonix Pharmaceuticals Holding Revenues and Earnings Miss Expectations Revenue missed analyst estimates by 18%. Earnings per share (EPS) also missed analyst estimates by 20%. Looking ahead, revenue is forecast to grow 84% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in the US. Performance of the American Biotechs industry. The company's shares are up 10% from a week ago. Risk Analysis You should learn about the 3 warning signs we've spotted with Tonix Pharmaceuticals Holding (including 2 which are potentially serious). Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data